Biohaven Ltd.

Equities

BHVN

VGG1110E1079

Biotechnology & Medical Research

End-of-day quote Nyse Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
35.1 ^USD	-0.37%		-4.41%	-17.99%

May. 29	Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day	CI
May. 29	Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate BHV-1510 in Advanced or Metastatic Epithelial Tumors	CI

Biohaven Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 29, 2024 at 04:05 pm EST

Biohaven Ltd. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 144.76 million compared to USD 201.11 million a year ago. Basic loss per share from continuing operations was USD 1.81 compared to USD 3.32 a year ago.

For the full year, the company reported net loss was USD 408.17 million compared to USD 570.28 million a year ago. Basic loss per share from continuing operations was USD 5.73 compared to USD 12.75 a year ago.

Latest news about Biohaven Ltd.

Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day	May. 29	CI
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate BHV-1510 in Advanced or Metastatic Epithelial Tumors	May. 29	CI
Certain Stock Options of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 18-MAY-2024.	May. 17	CI
Certain Common Shares of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 18-MAY-2024.	May. 17	CI
Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing	May. 15	MT
Biohaven Insider Bought Shares Worth $1,002,470, According to a Recent SEC Filing	May. 14	MT
Biohaven Shares Fall as Q1 Loss Widens, Misses Estimates	May. 10	MT
Biohaven Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing	Apr. 25	MT
Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO	Apr. 23	MT
Biohaven Insider Bought Shares Worth $7,999,961, According to a Recent SEC Filing	Apr. 23	MT
Biohaven Insider Bought Shares Worth $4,999,991, According to a Recent SEC Filing	Apr. 23	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Apr. 18	MT
Biohaven Prices $230 Million Public Share Offering	Apr. 18	MT
Biohaven Launches $200 Million Common Stock Offering	Apr. 17	MT
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Biohaven Q4 Non-GAAP Net Loss Widens, Shares Fall After-Hours	Feb. 29	MT
Biohaven Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Biohaven Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Biohaven Ltd. acquired Pyramid Biosciences, Inc. for $50 million.	Feb. 28	CI
Biohaven Insider Sold Shares Worth $459,663, According to a Recent SEC Filing	Jan. 02	MT
Certain Common Shares of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 17-NOV-2023.	Nov. 16	CI
Certain Stock Options of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 17-NOV-2023.	Nov. 16	CI
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Biohaven Pharmaceutical Q3 Net Loss Narrows	Nov. 14	MT

Chart Biohaven Ltd.

Duration

Period

More charts

Company Profile

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.

Sector

Biotechnology & Medical Research

Calendar

2024-07-28 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

35.1 USD

Average target price

56.89 USD

Spread / Average Target

+62.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOHAVEN LTD.	-17.99%	3.1B
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research